ABT
ABBOTT LABORATORIES
$88.18
-1.64%
$153.6B
No data for this timeframe.
Vol
Market Cap$153.6B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (71%)
Inst. Holders50 funds
Inst. Value$92.0B
Inst. Activity32 buys / 18 sells
Insider Activity2B / 6S
Insider Net $$642.5K
Reddit Sentiment71° Bullish
SEC Reports12
Congressional8 trades
Recent Activity
Jul 15, 2026
earnings_calendar
ABT Q2 2026 Earnings Before Market Open — 2026-07-15
EPS est: $1.39 | Rev est: $12.1B
Jun 13, 2026
SEC
The court denied plaintiffs' motion for sanctions against Abbott and denied their request to reopen discovery in this in
COURT-RULING — Impact 4/10
Jun 8, 2026
Event
United States v. James Abbott
Court ruling from Court of Appeals for the D.C. Circuit. Docket: 25-5352
May 31, 2026
SEC
5 firms acted on ABT: Freedom Broker, Benchmark, Jefferies, Oppenheimer, Piper Sandler
ANALYST-UPGRADE — Impact 4/10
May 27, 2026
Congress
Josh Gottheimer sell
$1,001 - $15,000 — House
May 1, 2026
SEC
Freedom Broker upgrades ABT to Buy — PT $120 (+32% upside) on cluster action
ANALYST-UPGRADE — Impact 4/10
Apr 28, 2026
Insider
Moreland Mary K acquired 5,314 shares
EXECUTIVE VICE PRESIDENT @ $94.41 ($501.7K)
Apr 27, 2026
Insider
STARKS DANIEL J bought 10,000 shares
Director @ $92.65 ($926.5K)
Price Targets
$116.54
+32.2% upside
Strong Buy
Current $88.18
Low $92.00
Median $115.00
High $135.00
24 analysts
$92.00
$135.00
Analyst Ratings
10Strong Buy
14Buy
10Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2026 | BTIG | REITERATE | Buy → Buy |
| Apr 20, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 17, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 17, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Apr 17, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.28 | $1.26 — $1.29 | 1% YoY | 22 |
| Next Q | $1.42 | $1.40 — $1.45 | 9% YoY | 22 |
| Current FY | $5.48 | $5.40 — $5.71 | 6% YoY | 24 |
| Next FY | $6.06 | $5.95 — $6.20 | 11% YoY | 24 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $15.0B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $11.6B | — |
| STATE STREET CORP | $8.2B | — |
| Capital Research Global Investors | $5.1B | ADD |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4.9B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 28, 2026 | Moreland Mary | I | $501.7K |
| Apr 27, 2026 | STARKS DANIEL | BUY | $926.5K |
| Apr 24, 2026 | Ahuja Nita | A | $0.00 |
| Apr 24, 2026 | Babineaux-Fontenot Claire | A | $0.00 |
| Apr 24, 2026 | Blount Sally | A | $0.00 |
Reddit Sentiment
71°▼
Bullish
Bearish
Neutral
Bullish
Congressional Trades
6 members: 3 buys, 4 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Josh Gottheimer | D | SELL | $1,001 - $15,000 |
| Laura Friedman | D | EXCHANGE | $1,001 - $15,000 |
| Rich McCormick | R | BUY | $1,001 - $15,000 |
50 institutional holders with $92.0B total value (894,646,728 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 145,687,458 | $15.0B | 16.2% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 112,949,933 | $11.6B | 12.6% | — |
| 3 | STATE STREET CORP | 79,575,468 | $8.2B | 8.9% | — |
| 4 | Capital Research Global Investors | 49,775,362 | $5.1B | 5.6% | ADD +27.1% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 47,944,891 | $4.9B | 5.3% | — |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 45,500,055 | $4.7B | 5.1% | DOUBLED +245.0% |
| 7 | Capital International Investors | 37,498,227 | $3.8B | 4.2% | TRIM -40.7% |
| 8 | MORGAN STANLEY | 30,101,596 | $3.1B | 3.4% | — |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 27,070,518 | $2.8B | 3.0% | — |
| 10 | FRANKLIN RESOURCES INC | 20,022,905 | $2.1B | 2.2% | ADD +79.5% |
| 11 | BANK OF AMERICA CORP /DE/ | 19,279,608 | $2.0B | 2.2% | — |
| 12 | WELLS FARGO & COMPANY/MN | 15,909,341 | $1.6B | 1.8% | — |
| 13 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 15,499,870 | $1.6B | 1.8% | — |
| 14 | GOLDMAN SACHS GROUP INC | 14,505,201 | $1.5B | 1.6% | — |
| 15 | DEUTSCHE BANK AG\ | 14,091,704 | $1.4B | 1.6% | — |
| 16 | AMERIPRISE FINANCIAL INC | 14,119,549 | $1.4B | 1.6% | — |
| 17 | Legal & General Group Plc | 12,285,529 | $1.3B | 1.4% | — |
| 18 | Nuveen, LLC | 11,191,853 | $1.1B | 1.2% | — |
| 19 | FMR LLC | 10,845,315 | $1.1B | 1.2% | — |
| 20 | Invesco Ltd. | 9,853,603 | $1.0B | 1.1% | TRIM -26.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Capital Research Global Investors | ADD | 39,169,239 | 49,775,362 | +27.1% | $5.1B | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 13,189,528 | 45,500,055 | +245.0% | $4.7B | 2026-Q1 |
| Capital International Investors | TRIM | 63,229,445 | 37,498,227 | -40.7% | $3.8B | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 11,155,088 | 20,022,905 | +79.5% | $2.1B | 2026-Q1 |
| Invesco Ltd. | TRIM | 13,340,991 | 9,853,603 | -26.1% | $1.0B | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 1,741,820 | 5,522,222 | +217.0% | $567.0M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 3,057,084 | 5,116,192 | +67.4% | $525.3M | 2026-Q1 |
| Mitsubishi UFJ Asset Management Co., Ltd. | TRIM | 6,998,412 | 4,914,068 | -29.8% | $504.5M | 2026-Q1 |
| Assenagon Asset Management S.A. | DOUBLED | 1,099,203 | 4,429,571 | +303.0% | $454.8M | 2026-Q1 |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | ADD | 1,878,629 | 3,419,348 | +82.0% | $351.1M | 2026-Q1 |
| Neuberger Berman Group LLC | TRIM | 4,755,148 | 2,878,726 | -39.5% | $295.5M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 1,897,276 | 2,588,711 | +36.4% | $265.8M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 58,487 | 2,010,938 | +3338.3% | $206.5M | 2026-Q1 |
| FIFTH THIRD BANCORP | ADD | 1,278,539 | 1,906,560 | +49.1% | $195.7M | 2026-Q1 |
| Rockefeller Capital Management L.P. | TRIM | 2,948,458 | 1,533,594 | -48.0% | $157.5M | 2026-Q1 |
| Mirae Asset Global Investments Co., Ltd. | DOUBLED | 365,276 | 1,372,906 | +275.9% | $141.0M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | ADD | 981,504 | 1,326,079 | +35.1% | $136.1M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 558,066 | 1,238,666 | +122.0% | $127.2M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 1,650,567 | 1,175,305 | -28.8% | $120.7M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | NEW | — | 1,156,955 | — | $118.8M | 2026-Q1 |
| ING GROEP NV | ADD | 595,441 | 1,020,890 | +71.5% | $104.8M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | TRIM | 1,406,985 | 967,639 | -31.2% | $99.3M | 2026-Q1 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | TRIM | 1,214,297 | 890,970 | -26.6% | $91.5M | 2026-Q1 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | ADD | 548,204 | 884,654 | +61.4% | $90.8M | 2026-Q1 |
| M&T BANK CORP | DOUBLED | 72,405 | 854,942 | +1080.8% | $87.8M | 2026-Q1 |
24 unique insiders with 50 transactions. Net insider value: $642.5K ($1.1M bought, $485.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | I | 5,314 | $94.41 | $501.7K |
| Apr 27, 2026 | STARKS DANIEL J | Director | BUY | 10,000 | $92.65 | $926.5K |
| Apr 24, 2026 | Ahuja Nita | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | Babineaux-Fontenot Claire | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | Blount Sally E. | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | Gonzalez Patricia Paola | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | Kumbier Michelle | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | McDew Darren W | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | McKinstry Nancy | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | McKinstry Nancy | Director | AWARD | 2,305 | — | — |
| Apr 24, 2026 | Roman Michael F | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | O'Grady Michael | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | O'Grady Michael | Director | AWARD | 5,929 | — | — |
| Apr 24, 2026 | STARKS DANIEL J | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | STARKS DANIEL J | Director | AWARD | 7,105 | — | — |
| Apr 24, 2026 | Stratton John G | Director | AWARD | 2,286 | — | — |
| Apr 24, 2026 | Conroy Kevin T | Director | AWARD | 2,286 | — | — |
| Apr 23, 2026 | Boudreau Philip P | EVP AND CFO | I | 8,909 | $92.04 | $820.0K |
| Apr 23, 2026 | Boudreau Philip P | EVP AND CFO | BUY | 2,200 | $91.50 | $201.3K |
| Mar 31, 2026 | Roman Michael F | Director | AWARD | 367 | $102.67 | $37.7K |
| Mar 31, 2026 | Ahuja Nita | Director | AWARD | 102 | $102.67 | $10.5K |
| Mar 31, 2026 | Alpern Robert J | Director | AWARD | 76 | $102.67 | $7.8K |
| Mar 31, 2026 | Stratton John G | Director | AWARD | 382 | $102.67 | $39.2K |
| Mar 31, 2026 | Gonzalez Patricia Paola | Director | AWARD | 321 | $102.67 | $33.0K |
| Mar 23, 2026 | ORVILLE JACOB A | Senior Vice President | AWARD | 13,255 | — | — |
| Mar 2, 2026 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | SELL | 585 | $115.58 | $67.6K |
| Mar 2, 2026 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | SELL | 613 | $115.58 | $70.9K |
| Mar 2, 2026 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | SELL | 263 | $115.58 | $30.4K |
| Mar 2, 2026 | Shroff Eric | Senior Vice President | SELL | 709 | $115.58 | $81.9K |
| Mar 2, 2026 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | SELL | 885 | $115.58 | $102.3K |
| Mar 2, 2026 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | SELL | 1,144 | $115.58 | $132.2K |
| Feb 27, 2026 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | TAX W/H | 4,040 | $116.26 | $469.7K |
| Feb 27, 2026 | Scoggins Christopher J | EXECUTIVE VICE PRESIDENT | TAX W/H | 4,997 | $116.26 | $581.0K |
| Feb 27, 2026 | Boudreau Philip P | EVP AND CFO | TAX W/H | 7,441 | $116.26 | $865.1K |
| Feb 27, 2026 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | TAX W/H | 8,577 | $116.26 | $997.2K |
| Feb 27, 2026 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | TAX W/H | 1,142 | $116.26 | $132.8K |
| Feb 27, 2026 | Ford Robert B | CHAIRMAN AND CEO | TAX W/H | 30,308 | $116.26 | $3.5M |
| Feb 27, 2026 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | TAX W/H | 6,615 | $116.26 | $769.1K |
| Feb 27, 2026 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | TAX W/H | 1,421 | $116.26 | $165.2K |
| Feb 27, 2026 | Shroff Eric | Senior Vice President | TAX W/H | 1,384 | $116.26 | $160.9K |
| Feb 27, 2026 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | TAX W/H | 4,630 | $116.26 | $538.3K |
| Feb 24, 2026 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | AWARD | 61,964 | — | — |
| Feb 24, 2026 | Shroff Eric | Senior Vice President | AWARD | 44,821 | — | — |
| Feb 24, 2026 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | AWARD | 5,373 | — | — |
| Feb 24, 2026 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | AWARD | 22,151 | — | — |
| Feb 24, 2026 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | AWARD | 15,418 | — | — |
| Feb 24, 2026 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | AWARD | 21,644 | — | — |
| Feb 24, 2026 | Ford Robert B | CHAIRMAN AND CEO | AWARD | 83,464 | — | — |
| Feb 24, 2026 | Scoggins Christopher J | EXECUTIVE VICE PRESIDENT | AWARD | 18,502 | — | — |
| Feb 24, 2026 | Scoggins Christopher J | EXECUTIVE VICE PRESIDENT | AWARD | 76,273 | — | — |
12 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 8 neutral. Avg impact: 3.8/10.
BULLISH
ANALYST-UPGRADE
4/10
5 firms acted on ABT: Freedom Broker, Benchmark, Jefferies, Oppenheimer, Piper Sandler
May 31, 2026
MIXED
ANALYST-UPGRADE
4/10
Freedom Broker upgrades ABT to Buy — PT $120 (+32% upside) on cluster action
May 1, 2026
NEUTRAL
COURT-RULING
4/10
The court denied plaintiffs' motion for sanctions against Abbott and denied their request to reopen
Jun 13, 2026
NEUTRAL
COURT-RULING
1/10
The Ninth Circuit affirmed the district court's dismissal of a pro se plaintiff's employment claims
May 28, 2026
NEUTRAL
CLUSTER
2/10
Insider cluster at Abbott Laboratories shows two open-market purchases totaling $1.13M by the CFO an
Apr 28, 2026
NEUTRAL
8-K
2/10
Abbott Laboratories filed an 8-K reporting the adoption of amended and restated bylaws effective Apr
Apr 27, 2026
NEUTRAL
8-K
4/10
Abbott Laboratories has preliminarily agreed to settle a shareholder derivative lawsuit related to i
Apr 17, 2026
BEARISH
8-K
8/10
Abbott Laboratories reported first-quarter 2026 adjusted EPS of $1.15, a 6% year-over-year increase,
Apr 16, 2026
NEUTRAL
COURT-RULING
3/10
Analysis based on filing metadata only — document content was unavailable. Two court rulings against
Mar 30, 2026
BULLISH
8-K
8/10
Abbott Laboratories completed the acquisition of Exact Sciences for $105.00 per share in cash, estab
Mar 23, 2026
NEUTRAL
DEFA14A
3/10
This DEFA14A filing is a definitive additional proxy soliciting material from Abbott Laboratories (A
Mar 13, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Abbott Laboratories over the past week includes open-market sal
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (71% buy). Based on 34 analysts: 10 strong buy, 14 buy, 10 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$116.54 mean target
+32.2% upside
Strong Buy (1.67)
$92.00 Low
$135.00 High
| Metric | Value |
|---|---|
| Current Price | $88.18 |
| Target Low | $92.00 |
| Target Mean | $116.54 |
| Target Median | $115.00 |
| Target High | $135.00 |
| # Analysts | 24 |
| Recommendation | Strong Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.28 | $1.26 | $1.29 | 1.3% | -0.0% | 0↑ 2↓ | $12.5B | 12.5% | 22 |
| Next Q 2026-09-30 |
$1.42 | $1.40 | $1.45 | 9.2% | +0.1% | 1↑ 1↓ | $13.1B | 15.6% | 22 |
| Current FY 2026-12-31 |
$5.48 | $5.40 | $5.71 | 6.5% | +0.0% | 1↑ 2↓ | $50.3B | 13.5% | 24 |
| Next FY 2027-12-31 |
$6.06 | $5.95 | $6.20 | 10.5% | -0.1% | 0↑ 2↓ | $54.8B | 8.9% | 24 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.276 | |
| 7d ago | $1.276 | |
| 30d ago | $1.277 | -0.001 |
| 60d ago | $1.321 | -0.045 |
| 90d ago | $1.388 | -0.111 |
13 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 17, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 17, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Apr 17, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 17, 2026 | Benchmark | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Apr 17, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 9, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Mar 31, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 29, 2026 | Freedom Broker | UPGRADE | Hold | Buy |
| Jan 23, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Jan 23, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 23, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jan 23, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Jan 23, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 23, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Jan 5, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 14 | 10 | 0 | 0 | 71% | |
| May 1, 2026 | 10 | 15 | 10 | 0 | 0 | 71% | |
| Apr 1, 2026 | 10 | 16 | 9 | 0 | 0 | 74% | |
| Mar 1, 2026 | 10 | 15 | 10 | 0 | 0 | 71% | |
| Feb 1, 2026 | 10 | 15 | 10 | 0 | 0 | 71% | |
| Jan 1, 2026 | 10 | 14 | 11 | 0 | 0 | 69% | |
| Dec 1, 2025 | 10 | 14 | 11 | 0 | 0 | 69% | |
| Nov 1, 2025 | 10 | 14 | 12 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
6 members of Congress traded this stock: 3 buys, 4 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | Josh Gottheimer | D | HOUSE | SELL | $1,001 - $15,000 | Abbott Laboratories | Jun 4, 2026 (9d) |
| Mar 24, 2026 | Laura Friedman | D | HOUSE | EXCHANGE | $1,001 - $15,000 | Abbott Laboratories | Apr 20, 2026 (28d) |
| Mar 19, 2026 | Rich McCormick | R | HOUSE | BUY | $1,001 - $15,000 | Abbott Laboratories | Apr 8, 2026 (21d) |
| Mar 4, 2026 | Michael McCaul | R | HOUSE | SELL | $1,001 - $15,000 | Abbott Laboratories | Apr 10, 2026 (38d) |
| Feb 27, 2026 | Michael McCaul | R | HOUSE | SELL | $15,001 - $50,000 | Abbott Laboratories | Mar 12, 2026 (14d) |
| Feb 10, 2026 | Gilbert Cisneros | D | HOUSE | SELL | $1,001 - $15,000 | Abbott Laboratories | Mar 10, 2026 (29d) |
| Feb 5, 2026 | Michael McCaul | R | HOUSE | BUY | $15,001 - $50,000 | Abbott Laboratories | Mar 12, 2026 (36d) |
| Jan 29, 2026 | Thomas Kean Jr | R | HOUSE | BUY | $1,001 - $15,000 | Abbott Laboratories | Feb 20, 2026 (23d) |
71°
Bullish
Bearish
Neutral
Bullish
10 mentions
6 bullish
0 bearish
10 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 4, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Jun 4, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Jun 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Rotation into consumer staples/defensives - best plays?
▲ 1
💬 0
⚡ 0.5
ABOTT(ABT) opinions
▲ 1
💬 0
⚡ 0.5
Let’s talk about Abbot Labs (ABT)
▲ 1
💬 0
⚡ 0.5
Abbott: A Hidden Gem
▲ 1
💬 0
⚡ 0.5
$ABT is about to pop off tomorrow
▲ 1
💬 1
⚡ 0.5
Jul 15, 2026
earnings_calendar
ABT Q2 2026 Earnings Before Market Open — 2026-07-15
EPS est: $1.39 | Rev est: $12.1B
Jun 8, 2026
Enforcement
United States v. James Abbott
Court ruling from Court of Appeals for the D.C. Circuit. Docket: 25-5352
Jun 8, 2026
Enforcement
State v. Abbott
Court ruling from Ohio Court of Appeals. Docket: CA2024-12-084
May 28, 2026
Enforcement
Arakji v. Abbott Laboratories, Inc.
Court ruling from Court of Appeals for the Ninth Circuit. Docket: 24-7785
May 25, 2026
dark_pool
Dark Pool: ABT — 9.2M shares, 144,357 trades
Week starting 2026-05-25. Total ATS volume: 9,233,393 shares across 144,357 trades.
May 18, 2026
dark_pool
Dark Pool: ABT — 12.1M shares, 180,148 trades
Week starting 2026-05-18. Total ATS volume: 12,123,584 shares across 180,148 trades.
May 14, 2026
Clinical Trial
Quick Epidural Top-up With Alkalinized Lidocaine for Emergent Caesarean Delivery
Phase Phase 3 — COMPLETED
May 11, 2026
dark_pool
Dark Pool: ABT — 16.6M shares, 203,766 trades
Week starting 2026-05-11. Total ATS volume: 16,639,220 shares across 203,766 trades.
May 4, 2026
dark_pool
Dark Pool: ABT — 14.5M shares, 175,482 trades
Week starting 2026-05-04. Total ATS volume: 14,527,430 shares across 175,482 trades.
May 4, 2026
Enforcement
MacTruong v. Abbott
Court ruling from Court of Appeals for the Fifth Circuit. Docket: 25-50364
Apr 27, 2026
dark_pool
Dark Pool: ABT — 15.8M shares, 181,628 trades
Week starting 2026-04-27. Total ATS volume: 15,800,587 shares across 181,628 trades.
Apr 22, 2026
Enforcement
Judy Nicole Jacobs, et al. v. Abbott Laboratories, Inc., et al.
Court ruling from District Court, S.D. Texas. Docket: 3:23-cv-00132
Apr 21, 2026
short_interest
FTD: ABT — 6,240 shares ($0.6M) failed to deliver
Settlement: 20260421, Price: $96.00, FTD Value: $599,040, ABBOTT LABS;COM NPV
Apr 20, 2026
Clinical Trial
Use of Preoperative Sodium Bicarbonate Among Women With Obstructed Labor
Phase Phase 3 — COMPLETED
Apr 20, 2026
dark_pool
Dark Pool: ABT — 13.4M shares, 169,760 trades
Week starting 2026-04-20. Total ATS volume: 13,370,067 shares across 169,760 trades.
Apr 16, 2026
earnings_calendar
ABT Q1 2026 Earnings Before Market Open — 2026-04-16
Apr 14, 2026
earnings_calendar
ABT Q1 2026 Earnings Before Market Open — 2026-04-14
EPS est: $1.16 | Rev est: $11.1B
Apr 14, 2026
earnings_calendar
ABT Q1 2026 Earnings Before Market Open — 2026-04-14
Apr 13, 2026
dark_pool
Dark Pool: ABT — 20.1M shares, 226,930 trades
Week starting 2026-04-13. Total ATS volume: 20,111,741 shares across 226,930 trades.
Apr 13, 2026
short_interest
FTD: ABT — 68,600 shares ($6.9M) failed to deliver
Settlement: 20260413, Price: $100.30, FTD Value: $6,880,580, ABBOTT LABS;COM NPV
Apr 7, 2026
Clinical Trial
Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva
Phase Phase 3 — COMPLETED
Apr 6, 2026
dark_pool
Dark Pool: ABT — 10.4M shares, 131,756 trades
Week starting 2026-04-06. Total ATS volume: 10,434,791 shares across 131,756 trades.
Apr 3, 2026
Clinical Trial
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
Phase Phase 3 — COMPLETED
Mar 30, 2026
dark_pool
Dark Pool: ABT — 8.4M shares, 109,666 trades
Week starting 2026-03-30. Total ATS volume: 8,374,600 shares across 109,666 trades.
Feb 24, 2026
Clinical Trial
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
Phase Phase 2 — COMPLETED